FDA Strategizes to Step Up Introduction of Lower-Cost Drugs and NGS
Pharma & biotech2018-06-19
2 Views
The market for biosimilar introduction is “extremely unstable,” but the FDA is working to ease the launch of more affordable cancer medicines with a strategy that includes an attempt to reduce anticompetitive behavior.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
* Five Most Promising Investment Trends to Capitalize On in 2021
* Improving Your Security Online: 4 Simple Steps
